Washington's Interest in Precision Drugs is Innovation, Not Cost

Washington's Interest in Precision Drugs is Innovation, Not Cost-nationaljournal: As House, Senate, and White House attention shifts toward biomedical innovation, the high cost of specialty drugs remains unaddressed.